William Blair & Company’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.3M Sell
315,690
-29,110
-8% -$2.4M 0.07% 219
2025
Q4
$29.4M Sell
344,800
-27,553
-7% -$2.26M 0.08% 186
2025
Q3
$29M Sell
372,353
-17,780
-5% -$1.39M 0.08% 189
2025
Q2
$30.5M Sell
390,133
-30,093
-7% -$2.24M 0.08% 183
2025
Q1
$30.5M Sell
420,226
-106,066
-20% -$7.59M 0.09% 175
2024
Q4
$39M Sell
526,292
-77,310
-13% -$5.41M 0.11% 159
2024
Q3
$39.8M Sell
603,602
-123,931
-17% -$9M 0.12% 148
2024
Q2
$67.2M Sell
727,533
-193,243
-21% -$17.1M 0.21% 109
2024
Q1
$88M Sell
920,776
-24,905
-3% -$2.09M 0.28% 92
2023
Q4
$72.1M Sell
945,681
-59,594
-6% -$4.15M 0.25% 94
2023
Q3
$69.6M Sell
1,005,275
-56,394
-5% -$4.53M 0.27% 88
2023
Q2
$100M Buy
1,061,669
+32,547
+3% +$2.83M 0.37% 68
2023
Q1
$85.1M Sell
1,029,122
-78,820
-7% -$6.2M 0.34% 73
2022
Q4
$82.7M Sell
1,107,942
-33,739
-3% -$2.6M 0.36% 71
2022
Q3
$94.3M Buy
1,141,681
+189
+0% +$18.2K 0.43% 56
2022
Q2
$109M Buy
1,141,492
+218,926
+24% +$22.7M 0.48% 49
2022
Q1
$109M Sell
922,566
-22,902
-2% -$2.57M 0.38% 64
2021
Q4
$122M Buy
945,468
+21,684
+2% +$2.53M 0.38% 58
2021
Q3
$105M Sell
923,784
-629
-0.1% -$71.8K 0.36% 66
2021
Q2
$95.7M Buy
924,413
+28,241
+3% +$2.66M 0.33% 71
2021
Q1
$75M Sell
896,172
-2,678
-0.3% -$226K 0.28% 81
2020
Q4
$82M Buy
898,850
+16,425
+2% +$1.36M 0.3% 77
2020
Q3
$70.4M Sell
882,425
-7,981
-0.9% -$623K 0.3% 75
2020
Q2
$61.5M Buy
890,406
+1,770
+0.2% +$126K 0.29% 73
2020
Q1
$55.9M Sell
888,636
-25,371
-3% -$1.83M 0.35% 63
2019
Q4
$71.1M Sell
914,007
-4,335
-0.5% -$339K 0.37% 67
2019
Q3
$67.3M Buy
918,342
+3,429
+0.4% +$241K 0.39% 61
2019
Q2
$56.3M Buy
914,913
+37,770
+4% +$2.28M 0.32% 78
2019
Q1
$55.9M Buy
877,143
+27,183
+3% +$1.55M 0.34% 75
2018
Q4
$43.4M Sell
849,960
-9,843
-1% -$498K 0.32% 81
2018
Q3
$49.9M Sell
859,803
-21,774
-2% -$1.06M 0.31% 83
2018
Q2
$42.8M Sell
881,577
-160,209
-15% -$7.48M 0.29% 86
2018
Q1
$48.5M Sell
1,041,786
-426,348
-29% -$18.5M 0.34% 73
2017
Q4
$55.2M Sell
1,468,134
-41,889
-3% -$1.54M 0.37% 65
2017
Q3
$55M Sell
1,510,023
-22,083
-1% -$842K 0.41% 63
2017
Q2
$60.4M Buy
1,532,106
+174,441
+13% +$6.37M 0.45% 57
2017
Q1
$42.6M Buy
1,357,665
+324,957
+31% +$10.2M 0.34% 79
2016
Q4
$32.3M Buy
1,032,708
+953,286
+1,200% +$30.9M 0.29% 94
2016
Q3
$3.19M Buy
79,422
+15,927
+25% +$600K 0.03% 397
2016
Q2
$2.11M Buy
63,495
+11,124
+21% +$381K 0.02% 467
2016
Q1
$1.54M Buy
52,371
+13,785
+36% +$380K 0.01% 512
2015
Q4
$1.02M Buy
38,586
+25,830
+202% +$671K 0.01% 628
2015
Q3
$302K Sell
12,756
-6,438
-34% -$155K ﹤0.01% 1139
2015
Q2
$455K Sell
19,194
-26,184
-58% -$591K ﹤0.01% 1787
2015
Q1
$1.08M Buy
45,378
+12,030
+36% +$270K ﹤0.01% 1531
2014
Q4
$708K Buy
33,348
+19,206
+136% +$386K ﹤0.01% 1596
2014
Q3
$240K Sell
14,142
-3,150
-18% -$49.7K ﹤0.01% 1913
2014
Q2
$247K Hold
17,292
﹤0.01% 1877
2014
Q1
$213K Sell
17,292
-30,060
-63% -$347K ﹤0.01% 1885
2013
Q4
$519K Sell
47,352
-65,196
-58% -$735K ﹤0.01% 1581
2013
Q3
$1.3M Buy
112,548
+150
+0.1% +$1.75K ﹤0.01% 1262
2013
Q2
$1.26M Buy
+112,398
New +$1.33M ﹤0.01% 1198

Other funds holding EW

William Blair & Company's EW Position: Q1 2026 in Review

William Blair & Company reduced its Edwards Lifesciences (EW) stake by 8.4% in Q1 2026, selling an estimated $2.4M and leaving 315,690 shares worth $25.3M. The position accounts for 0.07% of the portfolio, ranked #219.

William Blair & Company first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $122M in Q4 2021. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • William Blair & Company held 315,690 shares of Edwards Lifesciences worth $25.3M as of Q1 2026.
  • William Blair & Company sold 29,110 Edwards Lifesciences shares in Q1 2026, an estimated $2.4M.
  • Edwards Lifesciences made up 0.07% of William Blair & Company's portfolio in Q1 2026, its #219 holding.
  • William Blair & Company first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • William Blair & Company's Edwards Lifesciences position peaked at $122M in Q4 2021.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.